Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFORM: FF/UMEC/VI vs ICS/LABA in Uncontrolled Asthma
NCT06372496Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2024
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 4 trial of fluticasone, umeclidinium, vilanterol trifenatate in asthma, sponsored by GSK. Started Apr 2024; status: active, not recruiting.
02
Drugs
fluticasoneumeclidiniumvilanterol trifenatate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06372496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372496.